Hua Hua

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

China Investment Corp. (CIC) is a wholly state-owned investment institution which was established in 2007 under the Company Law of the People's Republic of China to hold, manage and invest their mandated assets to maximize shareholder's value. Headquartered in Beijing, CIC's activities include domestic investments in debt securities denominated in foreign currencies and other financial products denominated in foreign currencies; overseas investments in debt securities, stocks, funds and derivative instruments and other financial products; domestic and overseas equity investments; overseas investments through external fund managers; provision of loans through entrusted financial institutions; management of entrusted foreign exchange assets; establishment of equity investment funds and fund management companies as a promoter and other businesses approved by the relevant governmental authorities. The firm invests in domestic financial institutions primarily through their wholly-owned subsidiary, Central Huijin Investment Ltd. While they operate independently, CIC remains accountable to the State Council of the People's Republic of China and, ultimately, to the citizens of the People's Republic of China. Their investments are not limited to any particular sector, geography or asset class and include equity, fixed-income and alternative assets.

Infervision Medical Technology Co., Ltd. engages in the research and development, and provision of artificial intelligence technology in assisting medical image diagnosis. Its AI medical products intended for disease screening and diagnosis, disease intervention and treatment, patient management and medical research, for full-hospital deployment serving physicians from multiple departments. The firm’s products include InferRead Solution and InferScholar Center. The company was founded on January 5, 2016 and is headquartered in Beijing, China.